Clinical TrialsRisks include negative data from the camonsertib and lunresertib proof-of-concept trials and inability to advance these candidates into later-stage trials.
Regulatory And Market RisksKey risks to the price target include clinical, regulatory, and commercial risks, potential emergence of new competitors, and dilutive financing beyond what has been anticipated.
Stock PerformanceRoche terminating its camonsertib (ATRi) license agreement with Repare in mid-February sent RPTX shares into a nosedive that has reached unwarranted levels.